Condition: Metastatic Prostate Cancer · Sponsor: Santa Chiara Hospital
The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials and/or clinical settings. In order to maximise the utility of liquid biopsies for advanced PCa, PRIME is focused on the development of novel computational and sequencing approaches that integrate multiple information from plasma circulating elements: i) cell free DNA (cfDNA) gene mutation data with accurate quantitation of cfDNA structural genomic changes, ii) cfDNA genomic profiling with cfDNA methylation status, and iii) the information provided by extracellular vesicles (EVs) and EV-associated cargo (including DNA, RNA and proteins).
This description comes directly from the study's public registry record.
Orazio Caffo · +39 0461902121 · orazio.caffo@apss.tn.it
Always discuss trial participation with your own doctor first.
| Istituto Romagnolo per lo Studio dei Tumori | Meldola, Forlì-Cesena, Italy | Recruiting |
| Azienda Ospedaliera San Luigi | Orbassano, Torino, Italy | Recruiting |
| Istituto Oncologico Veneto | Padova, Italy | Recruiting |
| Santa Chiara Hospital | Trento, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06981377